Healthcare Costs and Absenteeism Among Caregivers of Adults with Partial-Onset Seizures: Analysis of Claims from an Employer Database
Epilepsy is a common neurologic disorder in the United States, with an estimated prevalence of 3.4 million cases, and approximately 150,000 new cases of epilepsy are diagnosed annually.
The Importance of Clinical and Economic Support Systems for Caregivers
Yihua Xu, PhD, Lavanya Sudharshan, MS, Ming-Ann Hsu, MPH, Andrew S. Koenig, DO, FACR, Joseph C. Cappelleri, PhD, MPH, MS, Wen F. Liu, PharmD, BCPS, Timothy W. Smith, Margaret K. Pasquale, PhD
Avery A. Rizio, PhD, Michelle K. White, PhD, Kristen L. McCausland, MPH, PhD, Tiffany P. Quock, MS, PhD, Spencer D. Guthrie, MS, MBA, MPH, Miyo Yokota, PhD, Martha Bayliss, MS, MSc
Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly
Melanoma is the fifth most common malignancy among men and the sixth most common malignancy among women in the United States. The American Cancer Society estimated that in 2018, 91,270 new cases of invasive melanoma will be diagnosed in the United States, and the disease will result in approximately 9320 deaths.
It’s About the Total Cost of Care
Computed Tomography Colonography Less Costly Than Colonoscopy for Colorectal Cancer Screening of Commercially Insured Patients
Tia Goss Sawhney, DrPH, FSA, MAAA, Bruce S. Pyenson, FSA, MAAA, David Rotter, PhD, Michele Berrios, Judy Yee, MD
In the United States, colorectal cancer (CRC) is the fourth most common cancer diagnosed among men and women and the second leading cause of death from cancer.1 The majority of cases of CRC can be prevented by the detection and removal of noncancerous adenomatous polyps (adenomas).
Alternative Payment Models in Medical Oncology: Assessing Quality-of-Care Outcomes Under Partial Capitation
Derek Ems, MPH, Sharanya Murty, PhD, Bryan Loy, MD, Judith Gallagher, MBA, Laura E. Happe, PharmD, MPH, Teresa L. Rogstad, MPH, Debra Finnel, Jimmy D. Fernandez, MD, MBA
Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes
Ivar S. Jensen, MBA, Elizabeth Wu, MPH, Naomi C. Sacks, PhD, Philip L. Cyr, MPH, Karen C. Chung, PharmD, MS
Trends in Utilization, Spending, and Prices of Smoking-Cessation Medications in Medicaid Programs: 25 Years Empirical Data Analysis, 1991-2015
Part of this information was presented as a poster at the 2016 Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
The Importance and Benefits of Smoking-Cessation Therapy
Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia
Craig White, PhD, Winghan Jacqueline Kwong, PharmD, PhD, Hilary Armstrong, PhD, Michael Behling, Research Associate, Jeffrey Niemira, Senior Statistician, Kathy Lang, PhD
Preliminary results of this study were presented as a poster at the American Society of Health-System Pharmacists 2017 Summer Meetings and Exhibition.
Real-World Drug Prescribing and Utilization Studies Can Inform Optimized Patient Care and Insurance Coverage
Estimating the Real-World Cost of Diabetes Mellitus in the United States During an 8-Year Period Using 2 Cost Methodologies
Vincent J. Willey, PharmD, Sheldon Kong, PhD, Bingcao Wu, MS, Amit Raval, PhD, Todd Hobbs, MD, Andrea Windsheimer, PharmD, Gaurav Deshpande, MS, PhD, Ozgur Tunceli, PhD, Brian Sakurada, PharmD, Jonathan R. Bouchard, MS, RPh
Diabetes mellitus imposes a substantial clinical and economic burden on the US healthcare system. National estimates reported in 2017 indicate that 9.4% of the US population, or 30.3 million Americans, have diabetes; however, only 23.1 million have actually been diagnosed with the disease, which means that 7.2 million people (or 23.8% of those with diabetes) were undiagnosed.
Page 1 of 6
Results 1 - 10 of 54
Results 1 - 10 of 54